Pmv Pharmaceuticals, Inc. (PMVP) — SEC Filings
Pmv Pharmaceuticals, Inc. (PMVP) — 29 SEC filings. Latest: ARS (Apr 22, 2026). Includes 10 SC 13G/A, 6 10-Q, 5 8-K.
View Pmv Pharmaceuticals, Inc. on SEC EDGAR
Overview
Pmv Pharmaceuticals, Inc. (PMVP) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a DEFA14A filed on Apr 22, 2026: PMV Pharmaceuticals, Inc. filed a DEFA14A on April 22, 2026, related to additional definitive proxy soliciting materials. The filing includes several documents, such as the DEFA14A itself and graphic files, totaling over 3.2 million characters in the complete submission text file. The company's prin
Sentiment Summary
Across 29 filings, the sentiment breakdown is: 1 bearish, 26 neutral, 2 mixed. The dominant filing sentiment for Pmv Pharmaceuticals, Inc. is neutral.
Filing Type Overview
Pmv Pharmaceuticals, Inc. (PMVP) has filed 1 ARS, 1 DEFA14A, 6 10-Q, 5 8-K, 2 DEF 14A, 2 10-K, 2 SC 13G, 10 SC 13G/A with the SEC between Jan 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (29)
Risk Profile
Risk Assessment: Of PMVP's 14 recent filings, 2 were flagged as high-risk, 5 as medium-risk, and 7 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | N/A |
| Net Income | -$21.059M |
| EPS | -$0.40 |
| Debt-to-Equity | N/A |
| Cash Position | $129.250M |
| Operating Margin | N/A |
| Total Assets | N/A |
| Total Debt | N/A |
Key Executives
- Kirsten Flowers
- Carol Gallagher, Pharm.D.
Industry Context
PMV Pharmaceuticals operates in the highly competitive and rapidly evolving precision oncology sector. This field is characterized by significant investment in research and development, a focus on targeted therapies based on genetic mutations, and a complex regulatory pathway. Companies in this space often rely heavily on external financing due to the long and expensive drug development process.
Top Tags
corporate-governance (4) · 10-Q (4) · pharmaceuticals (4) · financials (3) · institutional-ownership (3) · amendment (3) · sec-filing (2) · Biotechnology (2) · Oncology (2) · Clinical Stage (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Complete submission text file size | 3269571 | Indicates the volume of information provided in the filing. |
| DEFA14A document size | 15463 | Size of the primary proxy statement document. |
| Net loss for Q3 2025 | $21.059M | Increased from $19.226M in Q3 2024 |
| Net loss for nine months ended Sep 30, 2025 | $59.705M | Significantly widened from $35.709M in 2024 |
| Research and development expenses for nine months ended Sep 30, 2025 | $54.050M | Increased from $44.760M in 2024 |
| General and administrative expenses for nine months ended Sep 30, 2025 | $12.914M | Decreased from $15.520M in 2024 |
| Cash used in operating activities for nine months ended Sep 30, 2025 | $56.388M | Increased from $34.621M in 2024 |
| Cash, cash equivalents, and marketable securities as of Sep 30, 2025 | $129.250M | Decreased from $175.658M at Dec 31, 2024 |
| Accumulated deficit as of Sep 30, 2025 | $428.417M | Increased from $368.712M at Dec 31, 2024 |
| Shares of common stock outstanding as of Nov 12, 2025 | 53,211,507 | Reflects total shares outstanding |
| Net loss per share for Q3 2025 | $0.40 | Increased from $0.37 in Q3 2024 |
| Net loss per share for nine months ended Sep 30, 2025 | $1.14 | Increased from $0.69 in 2024 |
| Revenue | $0 | No revenue reported for Q2 2025 or the first six months, consistent with clinical-stage operations. |
| Net Loss (Q2 2025) | -$30.2M | Represents a decrease from -$36.5M in Q2 2024, indicating improved cost control. |
| Net Loss (YTD 2025) | -$62.3M | Lower than -$70.8M for the same period in 2024, reflecting reduced overall expenses. |
Frequently Asked Questions
What are the latest SEC filings for Pmv Pharmaceuticals, Inc. (PMVP)?
Pmv Pharmaceuticals, Inc. has 29 recent SEC filings from Jan 2024 to Apr 2026, including 10 SC 13G/A, 6 10-Q, 5 8-K. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of PMVP filings?
Across 29 filings, the sentiment breakdown is: 1 bearish, 26 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Pmv Pharmaceuticals, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Pmv Pharmaceuticals, Inc. (PMVP) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Pmv Pharmaceuticals, Inc.?
Key financial highlights from Pmv Pharmaceuticals, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for PMVP?
The investment thesis for PMVP includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Pmv Pharmaceuticals, Inc.?
Key executives identified across Pmv Pharmaceuticals, Inc.'s filings include Kirsten Flowers, Carol Gallagher, Pharm.D..
What are the main risk factors for Pmv Pharmaceuticals, Inc. stock?
Of PMVP's 14 assessed filings, 2 were flagged high-risk, 5 medium-risk, and 7 low-risk.
What are recent predictions and forward guidance from Pmv Pharmaceuticals, Inc.?
Forward guidance and predictions for Pmv Pharmaceuticals, Inc. are extracted from SEC filings as they are enriched.